Cargando…
Bone Marrow Mastocytosis: A Diagnostic Challenge
Bone marrow mastocytosis (BMM) represents a provisional, indolent subvariant of systemic mastocytosis (SM). Utilizing WHO criteria, BMM requires bone marrow (BM) involvement and the absence of mastocytosis skin lesions. BMM is characterized by male sex prevalence, a slight increase of serum tryptase...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037514/ https://www.ncbi.nlm.nih.gov/pubmed/33915965 http://dx.doi.org/10.3390/jcm10071420 |
_version_ | 1783677161539895296 |
---|---|
author | Zanotti, Roberta Tanasi, Ilaria Bernardelli, Andrea Orsolini, Giovanni Bonadonna, Patrizia |
author_facet | Zanotti, Roberta Tanasi, Ilaria Bernardelli, Andrea Orsolini, Giovanni Bonadonna, Patrizia |
author_sort | Zanotti, Roberta |
collection | PubMed |
description | Bone marrow mastocytosis (BMM) represents a provisional, indolent subvariant of systemic mastocytosis (SM). Utilizing WHO criteria, BMM requires bone marrow (BM) involvement and the absence of mastocytosis skin lesions. BMM is characterized by male sex prevalence, a slight increase of serum tryptase levels, low BM mast cells (MC) burden, and an indolent clinical course. BMM shows a strong correlation with severe anaphylaxis, mainly due to an IgE-mediated allergy to bee or wasp venom and, less frequently, to unexplained (idiopathic) anaphylaxis. Furthermore, BMM is often associated with osteoporosis which could be the only presenting symptom of the disease. BMM is an undervalued disease as serum tryptase levels are not routinely measured in the presence of unexplained osteoporosis or anaphylaxis. Moreover, BMM patients are often symptom-free except for severe allergic reactions. These factors, along with typical low BM MCs infiltration, may contribute to physicians overlooking BMM diagnosis, especially in medical centers that lack appropriately sensitive diagnostic techniques. This review highlights the need for a correct diagnostic pathway to diagnose BMM in patients with suspected symptoms but lacking typical skin lesions, even in the case of normal serum tryptase levels. Early diagnosis may prevent potential life-threatening anaphylaxis or severe skeletal complications. |
format | Online Article Text |
id | pubmed-8037514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80375142021-04-12 Bone Marrow Mastocytosis: A Diagnostic Challenge Zanotti, Roberta Tanasi, Ilaria Bernardelli, Andrea Orsolini, Giovanni Bonadonna, Patrizia J Clin Med Review Bone marrow mastocytosis (BMM) represents a provisional, indolent subvariant of systemic mastocytosis (SM). Utilizing WHO criteria, BMM requires bone marrow (BM) involvement and the absence of mastocytosis skin lesions. BMM is characterized by male sex prevalence, a slight increase of serum tryptase levels, low BM mast cells (MC) burden, and an indolent clinical course. BMM shows a strong correlation with severe anaphylaxis, mainly due to an IgE-mediated allergy to bee or wasp venom and, less frequently, to unexplained (idiopathic) anaphylaxis. Furthermore, BMM is often associated with osteoporosis which could be the only presenting symptom of the disease. BMM is an undervalued disease as serum tryptase levels are not routinely measured in the presence of unexplained osteoporosis or anaphylaxis. Moreover, BMM patients are often symptom-free except for severe allergic reactions. These factors, along with typical low BM MCs infiltration, may contribute to physicians overlooking BMM diagnosis, especially in medical centers that lack appropriately sensitive diagnostic techniques. This review highlights the need for a correct diagnostic pathway to diagnose BMM in patients with suspected symptoms but lacking typical skin lesions, even in the case of normal serum tryptase levels. Early diagnosis may prevent potential life-threatening anaphylaxis or severe skeletal complications. MDPI 2021-04-01 /pmc/articles/PMC8037514/ /pubmed/33915965 http://dx.doi.org/10.3390/jcm10071420 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zanotti, Roberta Tanasi, Ilaria Bernardelli, Andrea Orsolini, Giovanni Bonadonna, Patrizia Bone Marrow Mastocytosis: A Diagnostic Challenge |
title | Bone Marrow Mastocytosis: A Diagnostic Challenge |
title_full | Bone Marrow Mastocytosis: A Diagnostic Challenge |
title_fullStr | Bone Marrow Mastocytosis: A Diagnostic Challenge |
title_full_unstemmed | Bone Marrow Mastocytosis: A Diagnostic Challenge |
title_short | Bone Marrow Mastocytosis: A Diagnostic Challenge |
title_sort | bone marrow mastocytosis: a diagnostic challenge |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037514/ https://www.ncbi.nlm.nih.gov/pubmed/33915965 http://dx.doi.org/10.3390/jcm10071420 |
work_keys_str_mv | AT zanottiroberta bonemarrowmastocytosisadiagnosticchallenge AT tanasiilaria bonemarrowmastocytosisadiagnosticchallenge AT bernardelliandrea bonemarrowmastocytosisadiagnosticchallenge AT orsolinigiovanni bonemarrowmastocytosisadiagnosticchallenge AT bonadonnapatrizia bonemarrowmastocytosisadiagnosticchallenge |